Journals / MN Kardiyoloji / 2002 / Cilt: 9 - Sayı: 6

Cardiac enzymes and troponin I levels displaying myocardial injury in patients with coronary artery disease undergoing succesfully percutaneous coronary interventions

Başarılı perkütan revaskülarizasyon uygulanan koroner arter hastalarında miyokardiyal hasarı göstermede kardiyak enzim ve troponin I düzeylerinin değeri

Pages
407–410
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consequently measurements of Tn I levels is a sensitive method that can be used to detect myocardial necrosis likely to develop during follow up of patients after PTCA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: We aimed to investigate the clinical value of cardiac enzymes and troponin I to detect the myocardial damage likely to develop in patients with coronary artery disease undergoing PTCA and intracoronary stenting.
📊
Key Findings & Data:MATERIAL AND METHOD: Forty nine males (81.7%) (mean age 63,2 ±8,6) and 11 females (mean age 65,6±8,2) as a total of 60 patients undergoing intervention were included in the study.
💡
Conclusion & Impact:Consequently measurements of Tn I levels is a sensitive method that can be used to detect myocardial necrosis likely to develop during follow up of patients after PTCA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Elektrokardiyografi · Stentler · Anjiyoplasti

Abstract

AIM: We aimed to investigate the clinical value of cardiac enzymes and troponin I to detect the myocardial damage likely to develop in patients with coronary artery disease undergoing PTCA and intracoronary stenting. MATERIAL AND METHOD: Forty nine males (81.7%) (mean age 63,2 ±8,6) and 11 females (mean age 65,6±8,2) as a total of 60 patients undergoing intervention were included in the study. Forty two of them (70,0%) were applied in coronary stenting. All cases were hospitalized. After 2 days long treatment, PTCA and/or stenting was performed. Three venous blood samples were taken from the patients just prior to the intervention and at 6th and 18th hours thereafter. Cardiac enzyme and troponin I levels were studied. Cases complicated by acute occlusion or angiographically demonstrated side-branch occlusion and patients undergoing PTCA during the course of acute myocardial infarction were excluded. RESULTS: Changes in the levels of Tn I didn't reach the cut-off point for infarction, that's 1,5 ng/ml. But, difference between the value measured prior to the intervention and at 6th and 18th hours thereafter was statistically significant (p<0,05). Levels of other cardiac markers didn't change before and after procedure (p>0,05). CONCLUSION: This minor damage may occur as a result of ischemia caused by inflation of balloon or a side branch occlusion that could not be demonstrated by angiographically can this damage. Consequently measurements of Tn I levels is a sensitive method that can be used to detect myocardial necrosis likely to develop during follow up of patients after PTCA.

Özet

AMAÇ: Çalışmamızda komplikasyonsuz PTCA ve intrakoroner stent uygulanan koroner arter hastalarında oluşabilecek minimal miyokard hasarının saptanmasında kardiyak enzimler ve cTn I nin klinik kullanılabilirliğini araştırdık. GEREÇ VE YÖNTEM: Çalışmaya toplam 71 hasta alındı. Bu hastalardan işlem sırasında AMI gelişen 1 hasta ve anjiyografik yan dal oklüzyonu gözlenen 10 hasta çalışma dışı bırakıldı. Sonuçta 49'u (%81,7) erkek, 11'i (%18,3) kadın 60 hasta çalışma grubunu oluşturdu. Tüm olgular işlem öncesi hastaneye yatırıldı. En az iki günlük tedaviden sonra PTCA ve/veya stent uygulandı. Hastalardan hemen işlem öncesinde bir defa, işlem sonrası 6 ve 18 saat olmak üzere iki kan örneği alındı. Kardiyak enzimler ve troponin I düzeyleri çalışıldı. PTCA sonrası akut oklüzyon gelişen, anjiyografik olarak gösterilebilen yan dal tıkanması olan ve akut miyokard infarktüsü seyrinde yapılan PTCA lar çalışma dışı bırakıldı. BULGULAR: Troponin düzeylerinde gözlenen değişiklikler troponin I için infarktüs cut-off sınırı olan 1,5 ng/ml ye ulaşmadı. Ancak işlem öncesi ile işlem sonrası 6 saat (1,29±0,72 ng/ml) ve 18. saat (1,10±0,53ng/ml) değerler arasında istatistiksel olarak anlamlı artış vardı (p 0,05). SONUÇ: İşlem öncesi ve sonrası cTnI düzeylerindeki farklılığın diğer kardiyak enzimlerin duyarlı olmadığı minimal miyokardiyal hasara bağlı olduğu düşünüldü. Bu minimal hasar balon şişirilmesi esnasında oluşan iskemi ve lezyon bölgesindeki anjiografik olarak görülemeyen küçük yan dal tıkanmasına bağlı olarak veya distal mikroembolizasyona bağlı olarak oluşabilir. Sonuç olarak Troponin I PTCA sonrası hastaların takibinde oluşabilecek minimal miyokardiyal nekrozun saptanmasında kullanılabilecek hassas bir metot olabileceği kanısına varıldı.

🔖

Cite This Article

AYDIN, M., ÖZEREN, A., TOKAÇ, M., YETER, E., GÖK, H. (2002). Cardiac enzymes and troponin I levels displaying myocardial injury in patients with coronary artery disease undergoing succesfully percutaneous coronary interventions. MN Kardiyoloji, Cilt: 9 - Sayı: 6, 407–410. https://ajindex.com/articles/297780

References (11)

  1. Yılmaz E, Nişancı Y. Miyokard hasarı tanısında Troponin T, T.Klin. Kard. 1995; 8:43-6.
  2. Hamm CW, Katus HA. New biochemical markers for myocardial cell injury. CurrOpin Cardiol 1995; 10:355-60.
  3. Alexander RW, Prat CM, Robert R. Diagnosis and management of patients with acute myocardial infarction. In: Alexander RW, Schlant AC, eds Hurst's the Heart, Newyork: Me Graww Hill 1998; 1345-61.
  4. Mair J, Genser N, Moandeli D, et al. Cardiac Troponin I in the diagnosis of myocardial infarction and injury. Clinical Chemica Acta 1996:2345:19-38.
  5. Lusher MS, Typheen IC, Rawkilde J, et al. (For Trim Study Group) Applicability of cardiac Troponin T and I for early risk stratification in unstable coronary artery disease, Circulation 1997; 96:2578-85.
  6. Wu AHB, Feng YJ. Biochemical differences between cTnT and cT and their significant for diagnosis of acute coronary syndromes P Heart J 1998:19(supply):N25-9. Hamm CW. Progress in the diagnosis of unstable angina and perspectives for treatment Eur Heart J.1998 19(supply N):N 48-N50 Hamm CW, Goldman BU, Herschem C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing fO| cardiac troponin T and I. The New England J Med.1997; 334:1648-53
  7. Adams JE, Bodor GS, Davila VG, et al. Cardiac troponin I.A marke with high specifity for cardiac injury. Circulation 1993; 88:101-6.
  8. Bertinchant JP, Larue C, Pernel I, et al. Release kinetics of seru cardiac troponin I in ischemic myocardial injury. Clin. Biochem 1996 29:587-94.
  9. Talasz H, Genses N, Mair J, et al. Side branch occlusion during percutaneous transluminal coronary angioplaty Lancet 1992-1 339:1380. La Vecchia L, Bedogni F, Finocchi G, et al. Troponin I and creatine] kinase-MB mass after elective coronary stenting. Coron Arteryi Dis. 1996; 7:535. Adams JE, Sicard GA, Allen BT, et al. Diagnosis of perioperativej myocardial infarction with measurement of cardiac troponin I. N Eng J Med 1994;330:670-4.
  10. Adams JE, Davilla-Roman VG, Bessey PQ, Blake DP, Ladenson SH, Jaffe AS. Improved detection of cardiac contusion with cardiacs troponin I. Am Heart J.1996; 131:308-12.
  11. Hunt AC, Chow SL, Shin MF, Chilton DC, Commins B. Release of Creatin Kinase-MB and cardiac specific troponin I following percutaneous transluminal coronary angioplasty Eur H J 1991; 12:690. Bertinchant JP, Polge A, Ledermann B, et al. Relation of minor] cardiac troponin I elevation to late cardiac events after uncomp­ licated elective successful percutaneous transluminal coronary angioplasty for